CASE 4 - 1999: Myocardial function improvement after hemofiltration in a septic patient

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 4, 1999, Pages 484-489

  Oppenheim Eden, Arieh ^a   Matot, Idit ^b   Perouansky, Misha ^b   Weiss, Yoram G ^b   Pollak, Arthur ^b   Pizov, Reuven ^b   Schetz, Miet ^b  

^a CARMEL MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Cardiac contractility; Cardiac function; Hemofiltration; Septic shock; Transesophageal echocardiography

Indexed keywords

AGED; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; FUNCTIONAL ASSESSMENT; HEART FUNCTION; HEMODYNAMIC MONITORING; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SEPSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION;

EID: 0032818159     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(99)90227-6     Document Type: Conference Paper

References (36)

1. Bone RC, Balk RA, Cerra FB, et al: ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-1655, 1992
2. Parrillo JE, Burch C, Shelhamer JH, et al: A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76:1539-1553, 1985
3. Heidemann SM, Ofenstein JP, Sarnaik AP: Efficacy of continuous arteriovenous hemofiltration in endotoxic shock. Circ Shock 44:183-187, 1994
4. Freeman BD, Yatsiv I, Natanson C, et al: Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. J Am Coll Surg 180:286-292, 1995
5. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21:522-526, 1993
6. Gomez A, Wang R, Unruh H, et al: Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 73:671-685, 1990
7. Parker MM, Suffredini AF, Natanson C, et al: Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 4:19-25, 1989
8. Grocott-Mason RM, Shah AM: Cardiac dysfunction in sepsis: New theories and clinical implications. Intensive Care Med 24:286-295, 1998
9. Saito T, Takanashi M, Gallagher E, et al: Corticosteroid effect on early β-adrenergic downregulation during circulatory shock: Hemodynamic study and β-adrenergic receptor assay. Intensive Care Med 21:204-210, 1995
10. Lefer A, Rovetto M: Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc Soc Exp Biol 134:269-273, 1970
11. Kumar A, Thota V, Dee L, et al: Tumor necrosis factor alpha and interleukin 1β are responsible for in vitro myocardial cell depression induced by septic shock. J Exp Med 183:949-958, 1996
12. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin - A randomized, double-blind, placebocontrolled trial. N Engl J Med 324:429-436, 1991
13. Cohen J, Carlet J, and the INTERSEPT Study Group: An international multi-center, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 24:1431-1440, 1996
14. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet-activating receptor antagonist BN 52021 in the treatment of severe sepsis: A randomised, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728, 1994
15. Bone RC, Fisher CJ, Clemmer TP, et al: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987
16. Schetz M, Ferdinande P, Van den Berghe G et al: Removal of pro-inflammatory cytokines with renal replacement therapy: Sense or nonsense? Intensive Care Med 21:169-176, 1995
17. Schetz M: Evidence-based analysis of the role of hemofiltration in sepsis and multiorgan dysfunction syndrome. Curr Opin Crit Care 3:434-441, 1997
18. Van Bommel EF, Hesse CJ, Jutte NH, et al: Cytokine kinetics (TNF-α, IL-1β, IL-6) during continuous hemofiltration; A laboratory and clinical study. Contrib Nephrol 116:62-75, 1995
19. Grootendorst AF, Van Bommel EFH, Van der Hoven B, et al: High-volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 18:235-240, 1992
20. Ronco C, Bellomo R: The evolving technology for continuous renal replacement therapy from current standards to high-volume hemofiltration. Curr Opin Crit Care 3:426-433, 1997
21. Schiffl H, Lang SM, Konig A, et al: Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 344:570-572, 1994
22. Silvester W: Blood-membrane interaction in continuous renal replacement therapies. Curr Opin Crit Care 3:420-425, 1997
23. Braun N, Rosenfeld S, Giolai M, et al: Effect of continuous hemodiafiltration on IL-6, TNF-α, C3a, and TCC in patients with SIRS/septic shock using two different membranes. Contrib Nephrol 116:89-98, 1995
24. Riegel W, Ziegenfuss T, Rose S, et al: Influence of venovenous hemofiltration on posttraumatic inflammation and hemodynamics. Contrib Nephrol 116:56-61, 1995
25. Cosentino F, Paganini E, Lockrem J, et al: Continuous arteriovenous hemofiltration in the adult respiratory distress syndrome. Contrib Nephrol 93:94-97, 1991
26. Astiz ME, Rackow EC: Septic shock. Lancet 351:1501-1505, 1998
27. Walley KR: Mechanisms of decreased cardiac function in sepsis, in Vincent JL (ed): 1997 Yearbook of Intensive Care and Emergency Medicine, Berlin Heidelberg, New York, Springer, 1997, pp 243-255
28. Van Bommel EFH: Should continuous renal replacement therapy be used for 'non-renal' indications in critically ill patients with shock? Resuscitation 33:257-270, 1997
29. De Vriese AS, Colardyn FA, Lameire NH: Continuous renal replacement therapies in sepsis: Do they matter?, in Vincent JL (ed): 1999 Yearbook of Intensive Care and Emergency Medicine, Berlin, Heidelberg, New York, Springer, 1999, pp 611-620
30. Riera-JASI; Vela-JLP; Quintana-MJL, et al: Cytokines clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis 30:483-488, 1997
31. Sander A, Armbruster W, Sander B, et al: Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFa plasma concentrations. Intensive Care Med 23:878-884, 1997
32. Kellum-JA, Johnson-JP, Kramer-D et al: Diffusive vs. convective therapy: Effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 26:1995-2000, 1998
33. Riera-JASI, Alted-E, Lozano-MJ, et al: Influence of continuous hemofiltration on the hemodynamics of trauma patients. Surgery 122:902-908, 1997
34. Bellomo R, Baldwin I, Cole L, Ronco C: Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int 53:S182-S185, 1998 (suppl 66)
35. Matamis D, Tsagourias M, Koletsos K, et al: Influence of continuous haemofiltration-related hypothermia on haemodynamic variables and gas exchange in septic patients. Intensive Care Med 20:431-436, 1994
36. Lonnemann G: Continuous hemofiltration (CVVH) has no effect on plasma cytokine levels but modulates whole blood TNFa production in septic patients with acute renal failure (ANV). Blood Purif 15:6 (A), 1997 (abstr)